Merck

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

In India there are between 8-10 million people with heart failure, making it one of the world's largest populations with the malady

Seagen has several clinical-stage oncology candidates, as well as four approved drugs including breast cancer therapy Tukysa

The study was jointly conducted by a team of doctors at Fortis C-DOC, G.D Hospital and Diabetes Institute, Jawaharlal Nehru Medical College and Hospital, and the Diabetes Foundation

The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker's COVID-19 treatment debuted with nearly $1 billion in sales. Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday. Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion. Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street's per-share projections of $1.53, according to a survey by the data firm FactSet. Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts. The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue. Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue. Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in ear

US drug firm defends its drug amid concerns over safety

2,510 new Covid cases reported in Mumbai on Wednesday, 82% higher than Tuesday, while Delhi reports 86% jump at 923 new infections

150 mn doses of Corbevax, Covovax expected monthly from March

Oral medication targets ribonucleic acid polymerase, a part of the virus that has not changed much after mutations in the Omicron variant.

A Food and Drug Administration panel voted 13-10 that the drug's benefits outweigh its risks, including potential birth defects if used during pregnancy

The European Medicines Agency said it has received a request from Merck to authorise its coronavirus antiviral, the first pill shown to treat COVID-19.

US advisors to meet this month to vote on authorisation

Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide

The pharmaceutical company Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the first pill that has been shown to treat the disease

If cleared by the Food and Drug Administration a decision that could come in a matter of weeks it would be the first pill shown to treat Covid

Potentially, the drug could be very cheap to manufacture and available at a low cost in developing nations, benefiting millions of people

Drug cuts hospitalisation, deaths by 50%, shows an analysis of a late-stage trial

Merck & Co said Friday that its experimental COVID-19 pill reduced hospitalisations and deaths by half in people recently infected with the coronavirus and that it would soon ask health officials in the US and around the world to authorize its use. If cleared, Merck's drug would be the first pill shown to treat COVID-19, a potentially major advance in efforts to fight the pandemic. All COVID-19 therapies now authorised in the US require an IV or injection. Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalisation and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease. Among patients taking molnupiravir, 7.3 per cent were either hospitalised or died at the end of 30 .

Merck announced a donation of Rs 1.7 crore over two years to the IIT, Bombay to support the development of clinical tests for COVID-19 disease severity assessment

Science and technology firm Merck on Tuesday announced a support of 2 million euros (Rs 17.85 crore) for India to help the country fight against Covid-19